Breakout Bulletin: March 29-April 3

You're busy. Between patients, prior authorizations, and everything else on your plate, keeping up with the literature is the first thing that slips. The Breakout Bulletin is here to make sure it doesn't. Each week, we pull the most clinically relevant news from across dermatology and bring it straight to you — what's new, what it means, and what's worth watching. This week, we're coming off AAD 2026 in Denver, Colorado, and the meeting delivered. Here are the topics most likely to change how you practice.

Dermatomyositis Gets Its First Targeted Therapy

The VALOR trial — published in the New England Journal of Medicine — showed brepocitinib (Priovant Therapeutics) 30 mg once daily producing statistically significant improvements across muscle disease, skin disease, physical function, and steroid tapering over 52 weeks in adults with dermatomyositis. Nearly half of treated patients achieved a major response. More clinically pressing: 61.7% tapered to ≤2.5 mg prednisone-equivalent by weeks 48–52, versus 34.4% on placebo.¹

"These findings underscore the need to move beyond the historical paradigm of suboptimal disease control and reliance on systemic corticosteroids toward a patient-centric model focused on rapid, sustained, steroid-sparing efficacy with a modern, targeted therapy." — Ruth Ann Vleugels, MD, MPH, MBA, Mass General Brigham

FDA priority review is underway with a PDUFA date in Q3 2026. This would be the first specifically approved targeted therapy for DM — a disease managed on off-label regimens for decades.

READ MORE: Brepocitinib Results May End Decades of Steroid-Dependent Dermatomyositis Management

Oral Psoriasis Therapy Is Catching Up to Biologics

Two late-breaking datasets made the case that oral options are no longer a compromise. Envudeucitinib (ESK-001; Alumis), a next-generation TYK2 inhibitor, achieved PASI 90 in 65% and complete clearance in 40% of patients at week 24 in the ONWARD trials — numbers that would be respectable for an injectable.²

"It's pretty impressive to see an oral drug with 40% of the patients achieving complete clearance." — Andrew Blauvelt, MD

READ MORE: Phase 3 ONWARD Data Position Envudeucitinib as High-Efficacy Oral TYK2 Inhibitor in Psoriasis

Icotrokinra (Icotyde; Johnson & Johnson), a once-daily oral IL-23 antagonist, showed 50% of adults achieving total skin clearance at 52 weeks — rising to 60% in adolescents. Adverse event rates were within 1.1% of placebo. Investigators are already framing it as a potential first-line systemic.³ For the significant portion of your psoriasis patients who resist injectable therapy, both of these agents deserve close attention as they approach approval.

READ MORE: AAD 2026: 52-Week Icotrokinra Data Show High Rates of Skin Clearance and Consistent Safety in Plaque Psoriasis

Hidradenitis Suppurativa: Treat Earlier, Expect More

Three-year extension data for bimekizumab (Bimzelx; UCB) in HS told a consistent story: response deepens over time, and earlier treatment produces better long-term outcomes. HiSCR50 reached 90.2% at year 3, and point-in-time flare rates dropped to 0% among patients who remained on therapy. The disease duration analysis was the most actionable finding: patients treated earlier in a moderate disease stage achieved complete lesion clearance (HiSCR100) at more than twice the rate of those with long-standing severe disease.⁴

"Bimekizumab does work well for HS, and it seems to work better with time… We always do our primary outcomes at week 12 or 16, but we know that's not how long it takes HS to get better." — Steven Daveluy, MD, Wayne State University

READ MORE: Bimekizumab Shows Durable Responses in Psoriasis and HS Through 3 Years

Atopic Dermatitis: 4 Years Is Better Than 2

Lebrikizumab's (Ebglyss; Eli Lilly) ADlong extension study showed 94% of patients achieving EASI-75 and 68% reaching IGA 0/1 at up to 4 cumulative years of treatment — with 80% doing so without topical corticosteroids on a once-monthly schedule. The ceiling for response in committed, continuous IL-13 therapy is still rising. For patients who ask whether they'll need to be on this medication forever, the durability data at least makes that a more defensible conversation.⁵

READ MORE: Lebrikizumab Delivers Near-Complete Skin Clearance Without Topical Corticosteroids at 4 Years

The Field Has Outgrown Its Guidelines

Brian Kim, MD, offered the clearest framing of what all this data means for day-to-day practice:

"I just don't think it's going to be guidelines anymore. Because the guidelines will be outdated the moment you print it. It's really going to be a lot more about understanding what the drugs do, having experience with it in the clinic, and really taking much more of a personalized medicine approach."

MORE FROM KIM: Beyond Guidelines: Brian Kim, MD, on the Rapidly Evolving Itch and Dermatology Treatment Landscape

That shift lands squarely on the shoulders of NPs and PAs who are increasingly the primary managers of these patients. Staying current is no longer optional — it's the job.

References

1. New England Journal of Medicine publishes positive phase 3 VALOR trial results of brepocitinib in dermatomyositis. News release. Priovant Therapeutics. Published March 28, 2026. Accessed April 3, 2026. https://www.globenewswire.com/news-release/2026/03/28/3264202/34323/en/New-England-Journal-of-Medicine-Publishes-Positive-Phase-3-VALOR-Trial-Results-of-Brepocitinib-in-Dermatomyositis.html
2. Alumis’ envudeucitinib delivers early and robust improvements in skin clearance, quality of life, and psoriasis symptoms in two phase 3 trials, underscoring its potential as a leading oral therapy for plaque psoriasis. News release. Alumis. March 28, 2026. Accessed April 3, 2026. https://investors.alumis.com/news-releases/news-release-details/alumis-envudeucitinib-delivers-early-and-robust-improvements
3. ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis. News release. Johnson & Johnson. March 28, 2026. Accessed April 3, 2026. https://www.investor.jnj.com/investor-news/news-details/2026/ICOTYDE-icotrokinra-one-year-results-confirm-lasting-skin-clearance-and-favorable-safety-profile-in-oncedaily-pill-for-plaque-psoriasis/default.aspx
4. UCB announces new BIMZELX (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa. News release. UCB. March 27, 2026. Accessed April 3, 2026. https://www.ucb.com/newsroom/press-releases/article/ucb-announces-new-bimzelxr-bimekizumab-bkzx-data-at-aad-showing-durable-symptom-control-throughout-three-years-in-hidradenitis-suppurativa
5. Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis. News release. Almirall. Published March 27, 2026. Accessed April 3, 2026. https://www.almirall.com/newsroom/news/lebrikizumab-delivered-long-term-disease-control-for-up-to-four-years-in-patients-with-moderate-to-severe-atopic-dermatitis